T Cell News and Research

Latest T Cell News and Research

Research grants on facioscapulohumeral dystrophy prove useful as genetic basis is found

Businessman Bill Moss’s determination to fight his untreatable muscle-wasting disease may have paid off. Four years ago, Mr Moss, a former Macquarie Bank Executive Director, established a charitable research foundation, FSHD Global, which partly funded the Italian researchers who made the breakthrough.

8 May 2012

DFG to establish seven new research units

The establishment of six new Research Units and one Clinical Research Unit has been decided by the Joint Committee of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation). These networks will offer researchers the opportunity to address current and pressing issues in their fields and to pioneer innovative approaches. As all DFG Research Units, the new groups will work across locations and disciplines. Clinical Research Units combine clinical, applied and basic research.

8 May 2012

Researchers discover potential way to develop universal flu vaccines

University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations.

8 May 2012

Metformin blocks uveitis in laboratory rats

University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.

8 May 2012

Scientists make important discovery about internal programming of B cells

Scientists at The Scripps Research Institute have made an important discovery about the internal programming of B cells, the immune cells that make antibodies against infections. The finding opens the way for the development of vaccines that can work more efficiently and hints at therapies for conditions in which B cells cause harm—such as the autoimmune disease lupus erythymatosus, severe allergies, and B-cell lymphomas.

8 May 2012

FDA approves Clinigen’s Foscavir sNDA to treat HIV/AIDS-related CMV infections and herpes

Clinigen Healthcare, the pharmaceutical products division of Clinigen Group, announced today that its supplemental new drug application (sNDA) for Foscavir (foscarnet sodium), a treatment for HIV/AIDS-related cytomegalovirus (CMV) infections and herpes, has been approved by the US Food and Drug Administration.

From Clinigen Group 8 May 2012

Research reveals possible strategy to reverse fibrosis in liver and other organs

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, report that significant numbers of myofibroblasts - cells that produce the fibrous scarring in chronic liver injury - revert to an inactive phenotype as the liver heals. The discovery in mouse models could ultimately help lead to new human therapies for reversing fibrosis in the liver, and in other organs like the lungs and kidneys.

8 May 2012

Soon a single therapy for range of brain diseases like Parkinson’s and Alzheimer’s

In a study, published in Nature, researchers prevented brain cells dying in mice with prion disease. It is hoped the same method for preventing brain cell death could apply in other diseases. The findings are at an early stage, but have been heralded as “fascinating”.

8 May 2012

Campaign announces search for Arizona teens to participate in Addicteen

Arizona's anti-smoking youth campaign, Venomocity Brought to You by Addiction announces a search for Arizona teens to participate in Addicteen, a documentary about addiction. The film will examine activities which teenagers have defined as being addictive including, texting, social media and the use of tobacco. Filmmakers seek to draw out the similarities, differences and impacts of these behaviors on the lives of today's youth.

8 May 2012

T2M cells play a crucial role in treatment-resistant asthma

For most people with asthma, a couple of puffs from an inhaler filled with steroids makes breathing easy. But if their lungs become resistant to the calming effect of that medicine, they live in fear of severe asthma attacks that could send them to the hospital - or worse. Now, new research from the University of Michigan Health System may help explain what's going on in the lungs of these steroid-resistant individuals. The findings could aid the development of new treatment options, and of better ways to identify people at risk of becoming steroid-resistant.

8 May 2012

Researchers discover CD19 pathway that leads to lymphoma

Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma.

8 May 2012

Zinc oxide could increase risk of skin cancer

As vacationers prepare to spend time outdoors this summer, many of them will pack plenty of sunscreen in hopes it will protect their bodies from overexposure, and possibly from skin cancer. But researchers at Missouri University of Science and Technology are discovering that sunscreen may not be so safe after all.

8 May 2012

Affymax first quarter total revenue increases to $63.2 million

Affymax, Inc. today reported financial results for the first quarter ended March 31, 2012. The net income for the first quarter of 2012 was $31.5 million (or $0.87 per share) compared to a net loss of $9.6 million (or $(0.36) per share) for the first quarter of 2011.

8 May 2012

Healthy newborns should not be over-protected against natural exposure of gut flora

Infants whose gut is colonised by E. coli bacteria early in life have a higher number of memory B cells in their blood, reveals a study of infants carried out at the Sahlgrenska Academy at the University of Gothenburg, Sweden.

7 May 2012

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

7 May 2012

T Cell News and Research

Latest T Cell News and Research

Research grants on facioscapulohumeral dystrophy prove useful as genetic basis is found

DFG to establish seven new research units

Researchers discover potential way to develop universal flu vaccines

Metformin blocks uveitis in laboratory rats

Scientists make important discovery about internal programming of B cells

FDA approves Clinigen’s Foscavir sNDA to treat HIV/AIDS-related CMV infections and herpes

Research reveals possible strategy to reverse fibrosis in liver and other organs

Soon a single therapy for range of brain diseases like Parkinson’s and Alzheimer’s

Campaign announces search for Arizona teens to participate in Addicteen

T2M cells play a crucial role in treatment-resistant asthma

Researchers discover CD19 pathway that leads to lymphoma

Zinc oxide could increase risk of skin cancer

Affymax first quarter total revenue increases to $63.2 million

Healthy newborns should not be over-protected against natural exposure of gut flora

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Latest science from area of network biology

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

ADVENTRX first quarter net loss increases to $4.2M

CNV in prostate cancer tumors may accurately predict relapse

Researchers discover how diabetes affects specific brain area leading to memory loss

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in